Search Result

Results for "

Oral availability

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) 17β-HSD (1) 5-HT Receptor (4) Acyltransferase (1) ADC Linker (1) Adrenergic Receptor (1) Akt (2) Aldose Reductase (1) AMPK (1) Amyloid-β (4) Anaplastic lymphoma kinase (ALK) (6) Androgen Receptor (7) Angiotensin Receptor (1) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (9) AP-1 (1) Apoptosis (46) Aurora Kinase (3) Autophagy (18) Bacterial (19) Bcl-2 Family (1) Bcr-Abl (8) Beta-secretase (2) Biochemical Assay Reagents (5) Btk (2) c-Fms (1) c-Kit (3) c-Met/HGFR (2) c-Myc (2) Calcium Channel (4) Cannabinoid Receptor (1) Caspase (2) Cathepsin (2) CD73 (1) CDK (7) CFTR (2) Checkpoint Kinase (Chk) (1) Cholecystokinin Receptor (3) CMV (1) Complement System (2) COX (1) CXCR (5) Cytochrome P450 (1) Deubiquitinase (2) Dipeptidyl Peptidase (8) DNA-PK (1) DNA/RNA Synthesis (3) Dopamine Receptor (2) Drug Derivative (1) Drug Intermediate (2) Drug Isomer (1) Drug Metabolite (1) E1/E2/E3 Enzyme (2) EGFR (16) Endogenous Metabolite (9) Ephrin Receptor (1) Epigenetic Reader Domain (4) ERK (5) Estrogen Receptor/ERR (8) Eukaryotic Initiation Factor (eIF) (2) Factor Xa (1) FAK (2) Fatty Acid Synthase (FASN) (2) Ferroptosis (4) FGFR (7) Flavivirus (2) FLT3 (12) Free Fatty Acid Receptor (1) Fungal (6) FXR (1) GABA Receptor (3) GHSR (1) Glucocorticoid Receptor (1) Glucosylceramide Synthase (GCS) (4) Glycosyltransferase (1) GlyT (2) GnRH Receptor (1) GPR119 (5) GPR4 (1) Guanylate Cyclase (2) HBV (1) HCV (1) HDAC (2) Histamine Receptor (3) Histone Demethylase (2) Histone Methyltransferase (3) HIV (10) HIV Protease (1) HSP (3) HSV (2) IFNAR (3) iGluR (1) IKK (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Influenza Virus (3) Insulin Receptor (1) Interleukin Related (10) IRE1 (1) Isocitrate Dehydrogenase (IDH) (6) Isotope-Labeled Compounds (22) JAK (11) JNK (1) Leukotriene Receptor (2) Ligands for Target Protein for PROTAC (1) Liposome (1) Lipoxygenase (1) LPL Receptor (2) mAChR (1) Macrophage migration inhibitory factor (MIF) (1) MAGL (1) MAP3K (2) MCHR1 (GPR24) (1) MDM-2/p53 (6) MEK (4) mGluR (1) Mineralocorticoid Receptor (5) Mitochondrial Metabolism (2) Mixed Lineage Kinase (2) MNK (1) Molecular Glues (3) mTOR (3) nAChR (1) Neurokinin Receptor (1) Neuropeptide Y Receptor (1) NF-κB (8) NOD-like Receptor (NLR) (5) Nucleoside Antimetabolite/Analog (2) Opioid Receptor (2) Orexin Receptor (OX Receptor) (1) Orthopoxvirus (2) P-glycoprotein (1) P2X Receptor (1) P2Y Receptor (3) p38 MAPK (2) PAI-1 (5) PAK (5) Parasite (7) PARP (4) PDGFR (6) PERK (1) Phosphatase (3) Phosphodiesterase (PDE) (11) Phospholipase (3) Phosphomannose Isomerase (PMI) (1) PI3K (6) Pim (3) Platelet-activating Factor Receptor (PAFR) (1) Polo-like Kinase (PLK) (5) Porcupine (1) Potassium Channel (3) PPAR (2) Procollagen C Proteinase (1) Progesterone Receptor (1) Prostaglandin Receptor (9) PROTACs (1) Proteasome (1) Pyk2 (2) Raf (5) RAR/RXR (1) Ras (4) Reactive Oxygen Species (3) RET (3) Reverse Transcriptase (3) RIP kinase (1) ROR (4) ROS Kinase (1) SARS-CoV (1) Ser/Thr Kinase (1) Ser/Thr Protease (5) SGLT (2) SHP2 (1) Sodium Channel (4) Somatostatin Receptor (1) Src (5) STAT (2) STING (3) Syk (16) TAM Receptor (2) Thyroid Hormone Receptor (2) Tie (1) TNF Receptor (9) Toll-like Receptor (TLR) (2) Topoisomerase (1) Trace Amine-associated Receptor (TAAR) (1) Trk Receptor (1) TRP Channel (2) Tryptophan Hydroxylase (1) TSH Receptor (1) Tyrosinase (1) Vasopressin Receptor (1) VEGFR (11) Wnt (1) YAP (1)
By Research Areas:	Cancer (222) Cardiovascular Disease (39) Endocrinology (28) Infection (38) Inflammation/Immunology (85) Metabolic Disease (45) Neurological Disease (51)
Click Chemistry:	Azide (1)

422

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17359

Deferasirox 5+ Cited Publications ICL 670	Bacterial Ferroptosis	Cancer
Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload .

HY-145598

Sovleplenib HMPL-523	Syk	Cancer
Sovleplenib (HMPL-523) is a highly potent, orally available and selective SYK inhibitor with an IC₅₀ of 25 nM. Anti-tumor activity. Sovleplenib can be used for the research of immune thrombocytopenia (ITP) .

HY-19926

GDC-0425 RG-7602	Checkpoint Kinase (Chk)	Cancer
GDC-0425 (RG-7602) is an orally available, highly selective small molecule ChK1 inhibitor. GDC-0425 can be used for the research of various malignancies .

HY-107623

TC-MCH 7c	MCHR1 (GPR24)	Metabolic Disease
TC-MCH 7c, a phenylpyridone derivative, is an orally available, selective and brain-penetrable MCH₁R antagonist with an IC₅₀ of 5.6 nM for hMCH₁R . TC-MCH 7c has K_is of 3.4 nM and 3.0 nM of human and mouse MCH₁R, respectively .

HY-13540

E7016 GPI 21016	PARP	Cancer
E7016 (GPI 21016) is an orally available PARP inhibitor. E7016 can enhance tumor cell radiosensitivity in vitro and in vivo through the inhibition of DNA repair. E7016 acts as a potential anticancer agent .

HY-12085

Apremilast 5+ Cited Publications CC-10004	Phosphodiesterase (PDE) Apoptosis TNF Receptor	Inflammation/Immunology
Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC₅₀ of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC₅₀ of 104 nM .

HY-116524

PF-04781340	5-HT Receptor	Neurological Disease
PF-04781340 is a potent and selective 5-HT2C receptor agonist. PF-04781340 is orally available and have central nervous system penetrant profile .

HY-144110

HCV-IN-37	HCV	Infection
HCV-IN-37 (Compound 3d) is a potent inhibitor of HCV. HCV-IN-37 is orally available and long-lasting in rat plasma after oral administration to rats by a single dose of 15 mg/kg. The high potency of active derivative HCV-IN-37 is primarily driven by the inhibitory effect on the virus entry stage .

HY-14806S

Teneligliptin-d8 MP-513 d₈	Dipeptidyl Peptidase	Cardiovascular Disease
Teneligliptin-d₈ is a deuterium labeled Teneligliptin (MP-513). Teneligliptin is a potent, orally available, competitive, and long-lasting DPP-4 inhibitor[1].

HY-162517

UMM-766	Orthopoxvirus	Infection
UMM-766 is an orally available nucleoside analog. UMM-766 has potent, broad-spectrum antiviral activity against multiple members of the pox virus family. UMM-766 provides protection in a murine model of orthopox disease .

HY-106080A

Furegrelate sodium U-63557A	Prostaglandin Receptor	Cardiovascular Disease
Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC₅₀ of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .

HY-106080

Furegrelate U-63557A free acid	Prostaglandin Receptor	Cardiovascular Disease
Furegrelate (U-63557A free acid) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC₅₀ of 15 nM. Furegrelate is being developed as an antiplatelet agent .

HY-12085S

Apremilast-d5 CC-10004-d₅	Phosphodiesterase (PDE) TNF Receptor Apoptosis	Inflammation/Immunology
Apremilast-d₅ is a deuterium labeled Apremilast. Apremilast is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC50 of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC50 of 104 nM[1].

HY-12085R

Apremilast (Standard)	Phosphodiesterase (PDE) Apoptosis TNF Receptor	Inflammation/Immunology
Apremilast (Standard) is the analytical standard of Apremilast. This product is intended for research and analytical applications. Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC₅₀ of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC₅₀ of 104 nM .

HY-14806R

Teneligliptin (Standard)	Dipeptidyl Peptidase	Metabolic Disease
Teneligliptin (Standard) is the analytical standard of Teneligliptin. This product is intended for research and analytical applications. Teneligliptin (MP-513) is a potent, orally available, competitive, and long-lasting DPP-4 inhibitor. Teneligliptin competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC₅₀s of approximately 1 nM .

HY-128575

BNC375	nAChR	Neurological Disease
BNC375 is a potent, selective, and orally available type I positive allosteric modulator of α7 nAChRs with an EC₅₀ of 1.9 μM. BNC375 exhibits good CNS-agent like properties and clinical candidate potential. .

HY-112823A

Almonertinib mesylate 5 Publications Verification HS-10296 mesylate	EGFR	Cancer
Almonertinib (HS-10296) mesylate is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC₅₀: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib mesylate is used for the research of the non-small cell lung cancer .

HY-123356

EMD-503982	Factor Xa	Cardiovascular Disease
EMD-503982 is an orally available FXa inhibitor.

HY-142663

OI338	Insulin Receptor	Metabolic Disease
OI338 is an orally available, ultralong-acting insulin analogue.

HY-158100

SYD5115	TSH Receptor	Endocrinology
SYD5115 is an orally available TSH-R antagonist .

HY-16445

Sapacitabine CS682; CYC682	Nucleoside Antimetabolite/Analog	Cancer
Sapacitabine is an orally available nucleoside analog proagent that is structurally related to cytarabine.

HY-12507

GSK-7975A 10+ Cited Publications	Calcium Channel	Inflammation/Immunology
GSK-7975A is a potent and orally available CRAC channel inhibitor.

HY-16774

Vericiguat 5 Publications Verification BAY1021189	Guanylate Cyclase	Cardiovascular Disease Cancer
Vericiguat (BAY1021189) is a potent, orally available and soluble guanylate cyclase stimulator.

HY-10159

Nilotinib 35+ Cited Publications AMN107	Bcr-Abl Autophagy	Cancer
Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.

HY-110095

(±)-CPSI-1306 2 Publications Verification	Macrophage migration inhibitory factor (MIF)	Metabolic Disease Inflammation/Immunology
(±)-CPSI-1306 is an orally available antagonist of macrophage migration inhibitory factor (MIF).

HY-11077

SR 146131	Cholecystokinin Receptor	Metabolic Disease Endocrinology
SR 146131 is a potent, orally available, and selective nonpeptide (cholecystokinin 1) receptor agonist.

HY-10180

MLN8054 5+ Cited Publications	Aurora Kinase	Cancer
MLN8054 is a potent, selective and orally available aurora A kinase inhibitor with an IC₅₀ of 4 nM.

HY-145355

IDO1-IN-12	Indoleamine 2,3-Dioxygenase (IDO)	Cancer
IDO1-IN-12 is a potent and orally available IDO1 inhibitor.

HY-12727

EPZ015666 15+ Cited Publications GSK3235025	Histone Methyltransferase	Cancer
EPZ015666 (GSK3235025) is an orally available inhibitor of PRMT5 with an IC₅₀ of 22 nM.

HY-15828

Onvansertib 5+ Cited Publications NMS-1286937; NMS-P937	Polo-like Kinase (PLK) Apoptosis	Cancer
NMS-1286937 is a potent, selective and orally available PLK1 inhibitor, with an IC₅₀ of 2 nM.

HY-114332

GNE-8505	MAP3K	Neurological Disease
GNE-8505 is an orally available inhibitor of Dual leucine zipper kinase (DLK) .

HY-109032

Firuglipel DS-8500a	GPR119	Metabolic Disease
Firuglipel (DS-8500a) is an orally available, potent and selective GPR119 agonist.

HY-115777

ARN-6039	ROR	Neurological Disease
ARN-6039 is an orally available inverse agonist of RORγ for autoimmune demyelinating disease.

HY-13796

IPSU 1 Publications Verification	Orexin Receptor (OX Receptor)	Neurological Disease Endocrinology
IPSU is a selective, orally available and brain penetrant OX2R antagonist with a pK_i of 7.85.

HY-100388A

SHP099 monohydrochloride 60+ Cited Publications	SHP2 Phosphatase	Cancer
SHP099 hydrochloride is a potent, selective and orally available SHP2 inhibitor with an IC₅₀ of 70 nM .

HY-19741

A-1331852 35+ Cited Publications	Bcl-2 Family	Cancer
A-1331852 is an orally available BCL-XL selective inhibitor with a K_i of less than 10 pM.

HY-109018

Velagliflozin 1 Publications Verification	SGLT	Metabolic Disease
Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity.

HY-13742

Ropidoxuridine IPdR	HSV	Cancer
Ropidoxuridine (IPdR) is a novel orally available, halogenated thymidine analog and is a potential radiosensitizer for use in human tumors.

HY-169424

WRN inhibitor 18	DNA/RNA Synthesis	Cancer
WRN inhibitor 18 (compound 306) is an orally available inhibitor of WRN with in vivo anticancer activity .

HY-102013

Omilancor BT-11	Others	Neurological Disease Inflammation/Immunology
BT-11 is an orally available LANCL2 binding compound for treating inflammatory bowel disease.

HY-101611

MSC2530818	CDK	Cancer
MSC2530818 is a potent, selective and orally available CDK8 inhibitor with an IC₅₀ of 2.6 nM for CDK8.

HY-14832

Ataluren 5+ Cited Publications PTC124	CFTR Autophagy	Metabolic Disease Cancer
Ataluren (PTC124) is an orally available CFTR-G542X nonsense allele inhibitor.

HY-14870

Selexipag 2 Publications Verification NS-304; ACT-293987	Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI₂) receptor (IP receptor).

HY-15599

SSR128129E 1 Publications Verification SSR	FGFR	Cancer
SSR128129E is an orally available and allosteric FGFR inhibitor with an IC₅₀ of 1.9 μM for FGFR1.

HY-15411

MK-0557	Neuropeptide Y Receptor	Metabolic Disease Endocrinology
MK-0557 is a highly selective, orally available neuropeptide Y5 receptor antagonist with a K_i of 1.6 nM.

HY-15291

MBX-2982 10+ Cited Publications	GPR119	Metabolic Disease
MBX-2982 is a selective, orally-available G protein-coupled receptor 119 (GPR119) agonist.

HY-169207

NNRT-IN-5	Reverse Transcriptase	Cancer
NNRT-IN-5 (compund 10d) is an orally available non-nucleoside reverse transcriptase inhibitor .

HY-B0177

Tinidazole 1 Publications Verification	Bacterial Antibiotic Parasite	Infection Cancer
Tinidazole, an orally available antibacterial agent, is a 5-nitroimidazole with selective activity against anaerobic bacteria and protozoa .

HY-109082A

Cevidoplenib dimesylate SKI-O-703 dimesylate	Syk	Inflammation/Immunology
Cevidoplenib is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities .

HY-155944

Isbufylline	Phosphodiesterase (PDE)	Inflammation/Immunology
Isbufylline is a Phosphodiesterase inhibitor. Isbufylline is orally available. Isbufylline can be used in the research of respiratory diseases and inflammation such as asthma and pneumonia.

Cat. No.	Product Name

HY-L061

Orally Active Compound Library

4,170 compounds

Most of the drugs that are available in the marketplace are administered via the oral route, which is a convenient and cost effective route of administration. Thus, oral bioavailability is one of the key considerations in drug design and development. A high oral bioavailability reduces the amount of an administered drug necessary to achieve a desired pharmacological effect and therefore could reduce the risk of side-effects and toxicity. A poor oral bioavailability can result in low efficacy and higher inter-individual variability and therefore can lead to unpredictable response to a drug. Low oral bioavailability in clinical trials is a major reason for drug candidates failing to reach the market.

MCE offers a unique collection of 4,170 compounds with confirmed high oral bioavailability. MCE Orally Active Compound Library is a useful tool for discovering new drugs with oral bioavailability.

HY-L901P

Diversity Library Plus

80,000 compounds

A Lead-like, diverse library is the foundation for achieving biological activity diversity. The MCE Lead-like Diverse Library Plus is a further supplement to the 50K Lead-like Compound Library (HY-L901), consisting of over 80,000 lead-like compounds, with an additional 30,000 structurally novel lead-like molecules. These compounds occupy a broader "chemical space", making it a powerful tool for new drug discovery.

HY-L908

Lead-like Covalent Screening Library

1,049 compounds

Small molecule covalent inhibitors, or irreversible inhibitors, are a type of inhibitors that exert their biological functions by irreversibly binding to target through covalent bonds. Compared with non-covalent inhibitors, covalent inhibitors have obvious advantages in bioactivity, such that covalent warheads can target rare residues of a particular target protein, thus leading to the development of highly selective inhibitors and achieving a more complete and continued target occupancy in living systems. In recent years, the distinct strengths of covalent inhibitors in overcoming drug resistance had been recognized. However, toxicity can be a real challenge related to this class of therapeutics due to their potential for off-target reactivity and has led to these drugs being disfavored as a drug class. The drug design and optimization of covalent inhibitors has become a hot spot in drug discovery.

MCE Lead-like Covalent Screening Library offers a valuable resource of 1,049 lead-like compounds with commonly used covalent warheads. These warheads, such as acrylamide, activated terminal alkyne, acyloxymethyl ketone, and boronic acid, are capable of reacting with specific amino acid residues, including cysteine, lysine, serine, and histidine. The inclusion of these reactive warheads in the library allows researchers to explore the potential of covalent inhibition, a powerful approach in drug discovery.

HY-L906

Norepinephrine Transporter (NET) Compound Library

650 compounds

On May 15, 2024, "Dimerization and antidepressant recognition at noradrenaline transporter" was published online by Nature. The research findings were an effort from Shanghai Institute of Materia Medica, Chinese Academy of Sciences. This study unraveled the important neural system target - the noradrenaline transporter (NET), obtaining the binding modes of human NET homodimers with the natural substrate norepinephrine (NE) and six selective antidepressants. It laid an important theoretical foundation for understanding the physiological regulation mechanisms of NET and other monoamine transporters.

The Norepinephrine Transporter (NET) Compound Library is obtained by computer-aided virtual screening based on the HY-L901 compound library . The specific screening process includes molecular docking screening, key pharmacophore screening, and CNS-MPO screening, which can be used for new drug discovery targeting the noradrenaline transporter.

HY-L902

5K Scaffold Library

5,000 compounds

MCE 5K Scaffold Library consists of 5,000 lead-like compounds. Each compound represents one unique scaffold. All compounds are compatible with Lipinski’s rule (Rule of 5) with multiple characteristics such as calculated good solubility (-3.2 < logP < 5), oral bioavailability (RotB <= 10), drug transportability (PSA < 120). Compounds contained within the library have been screened to remove any inappropriate chemical structures, avoiding “false hits”. The sufficient diverse of compound structure makes this library a powerful tool for drug screening.

HY-L0121V

MCE 10K Natural Product-like Compound Library

10,000 compounds

Natural products are an attractive source with varied structures that exhibit potent biological activities, and desirable pharmacological profiles. The core scaffold of a natural product can also provide a biologically validated framework upon which to display diverse functional groups. Inspired by bioactive natural products, natural product-like compounds, occupying the same chemical space, are ideally suited to explore and to facilitate understanding of biological pathways.

MCE 10K Natural Product-like Compound Library consists of 10,000 natural product-like compounds. Each compound has scaffold of natural products or Tanimoto coefficient >0.6 with natural products. The natural-likeness scoring of these compounds is >-2. What’s more, compounds in the library are drug-like and readily available for re-supply, making it a powerful tool for new drug research and development. It can be widely applied in high-throughput screening (HTS) and high-content screening (HCS).

HY-L905

Natural Product-like Compound Library

5,000 compounds

MCE 5K Natural Product-like Compound Library consists of 5,000 natural product-like compounds. Each compound has scaffold of natural products or Tanimoto coefficient >0.6 with natural products. The natural-likeness scoring of these compounds is >-2. What’s more, compounds in the library are drug-like and readily available for re-supply, making it a powerful tool for new drug research and development. It can be widely applied in high-throughput screening (HTS) and high-content screening (HCS).

HY-L901

50K Diversity Library

50,000 compounds

MCE 50K Diversity Library consists of 50,000 lead-like compounds with multiple characteristics such as calculated good solubility (-3.2 < logP < 5), oral bioavailability (RotB <= 10), drug transportability (PSA < 120). These compounds were selected by dissimilarity search with an average Tanimoto Coefficient of 0.52. There are 36,857 unique scaffolds and each scaffold 1 to 7 compounds. What’s more, compounds with the same scaffold have as many functional groups as possible, which make abundant chemical spaces. This exceptionally diverse library is highly recommended for random screening against new as well as popular targets based its novel, diverse scaffolds, abundant chemical spaces and the convenience for subsequent modification.

Cat. No.	Product Name	Type

HY-114491

Rineterkib

Fluorescent Dyes/Probes

Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .

HY-10221G

Vorinostat (GMP) SAHA (GMP); Suberoylanilide hydroxamic acid (GMP)	Fluorescent Dye
Vorinostat (GMP) is a GMP grade Vorinosta (HY-10221). GMP-grade small molecules can be used as auxiliary agents in cell therapy. Vorinostat is a potent, orally available HDAC1, HDAC2, HDAC3 (Class I), HDAC6 and Inhibitors of HDAC7 (Class II) and Class IV (HDAC11) .

Cat. No.	Product Name	Type

HY-W012550

D-Carnitine	Biochemical Assay Reagents
D-Carnitine is an orally available isomer of the essential nutrient L-carnitine that promotes long-chain fatty acid transport into the mitochondrial matrix for beta-oxidation. D-Carnitine has antiparasitic activity .

HY-Y1147

Diethyl maleate

1 Publications Verification

Maleic acid diethyl ester

Biochemical Assay Reagents

Diethyl maleate (DEM) is an orally available, effective glutathione (GSH) depletor that crosses the blood-brain barrier. Diethyl maleate covalently binds irreversibly to GSH via glutathione S-transferase with an in vitro IC50 of 0.1-0.5 mM. Diethyl maleate selectively depletes GSH in liver, lung, and brain tissues, exacerbating oxidative stress and enhancing hyperbaric oxygen toxicity. Diethyl maleate promotes precursor amino acid uptake and in turn promotes GSH synthesis by upregulating the activity of the cystine-glutamate transporter X_{O ^-}. Diethyl maleate can be used to study redox homeostasis and GSH protection mechanisms in oxidative stress-related diseases such as hyperbaric oxygen injury and metabolic diseases[1][2][3].

HY-W012550R

D-Carnitine (Standard)	Biochemical Assay Reagents
D-Carnitine (Standard) is the analytical standard of D-Carnitine. This product is intended for research and analytical applications. D-Carnitine is an orally available isomer of the essential nutrient L-carnitine that promotes long-chain fatty acid transport into the mitochondrial matrix for beta-oxidation. D-Carnitine has antiparasitic activity .

HY-10221G

Vorinostat (GMP) SAHA (GMP); Suberoylanilide hydroxamic acid (GMP)	Biochemical Assay Reagents
Vorinostat (GMP) is a GMP grade Vorinosta (HY-10221). GMP-grade small molecules can be used as auxiliary agents in cell therapy. Vorinostat is a potent, orally available HDAC1, HDAC2, HDAC3 (Class I), HDAC6 and Inhibitors of HDAC7 (Class II) and Class IV (HDAC11) .

Cat. No.	Product Name	Target	Research Area

HY-P10587

Icotrokinra JNJ-77242113; JNJ-2113; PN-235	Interleukin Related STAT	Inflammation/Immunology
Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC₅₀=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC₅₀ of 18.4 pM. In addition, Icotrokinra exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease .

HY-156002

LUNA18 Paluratide	Ras ERK	Cancer
LUNA18 is an orally-available cyclic peptide KRAS and ERK inhibitor. LUNA18 phosphorylates ERK and AKT and decreases cell proliferation in RAS-mutated cancer cells. LUNA18 exhibits RAS signal inhibition and potent anti-cancer activities through inhibiting interaction between RAS and guanine nucleotide exchange factors (GEFs) in a mouse xenograft model. LUNA18 shows significant cellular efficacy against cell lines with KRAS genetic alterations, such as colon cancer, stomach cancer, non-small cell lung cancer and pancreaticcancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N3242

Moronic acid (+)-Moronic acid	Triterpenes Structural Classification Terpenoids Rhus chinensis Mill. Source classification Plants Anacardiaceae	HIV Reactive Oxygen Species NOD-like Receptor (NLR)
Moronic Acid is a triterpenoid compound, which is an orally available anti-HIV agent with anti-inflammatory activity. Moronic Acid can inhibit viral replication, with an EC₅₀ value of <1 μg/mL. Moronic Acid can be isolated from Brazilian propolis .

HY-N1394

p-Anisic acid 3 Publications Verification 4-Methoxybenzoic acid; Draconic acid	Infection Structural Classification Microorganisms Acacia mearnsii Classification of Application Fields Leguminosae Ketones, Aldehydes, Acids Cosmetic Research Plants Endogenous metabolite Disease Research Fields	Bacterial Endogenous Metabolite Tyrosinase
p-Anisic acid (4-Methoxybenzoic acid) is an orally available tyrosinase inhibitor that has antioxidant, anti-anxiety, anti-inflammatory, anti-tumor, anti-diabetic, and preservative properties. p-Anisic acid can be used as a preservative in the cosmetics field .

HY-W006405

Isoflavone	Structural Classification Flavonoids Classification of Application Fields Leguminosae Glycine max (L.) merr Source classification Other Diseases Plants Disease Research Fields Isoflavones	Estrogen Receptor/ERR
Isoflavone is an orally available bioactive component of soy phytoestrogen with lipid-lowering and antioxidant activities. Isoflavone prevents a variety of chronic diseases by regulating fatty acid oxidation in the liver and gene expression in adipose tissue. In addition, isoflavone has important value in the research of cancer and cardiovascular diseases .

HY-N1487

Oleanonic acid 1 Publications Verification 3-Oxooleanolic acid	Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Source classification Plants Disease Research Fields Cancer	HIV Autophagy Ferroptosis Amyloid-β
Oleanonic acid (3-Oxooleanolic acid) is an orally available triterpene that has anti-inflammatory and insecticidal properties. In vitro, oleanonic acid can improve oxidative stress, autophagy defects, ferroptosis, mitochondrial damage, and endoplasmic reticulum stress induced by Amyloid-β, and in vivo, it can alleviate myocardial hypertrophy in rats .

HY-77813

Benzyl isothiocyanate	Structural Classification Natural Products Classification of Application Fields Source classification Opiliaceae Plants Disease Research Fields Endocrinology Salvadora persica	Bacterial Apoptosis Antibiotic Parasite Autophagy Reactive Oxygen Species
Benzyl isothiocyanate is an orally available isothiocyanate with bactericidal, anticancer, antiangiogenic and anthelmintic activities. Benzyl isothiocyanate exerts anticancer functions by regulating multiple signaling pathways, including apoptosis, cell proliferation, cell cycle arrest, metastasis, angiogenesis, and autophagy. In addition, Benzyl isothiocyanate can enhance muscle insulin sensitivity to improve obesity-induced hyperglycemia .

HY-120657

9-PAHSA	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
9-PAHSA is an orally available anti-inflammatory lipid that lowers blood sugar and reduces inflammation. 9-PAHSA also improved carotid vascular calcification and attenuates cardiac hypertrophy and dysfunction in db/db mice. 9-PAHSA increases the viability of steatosis primary mouse hepatocytes (PMH). 9-PAHSA can be used in research on diabetes, inflammation, and cardiovascular disease .

HY-113365

Cholestenone 4-Cholesten-3-one	Structural Classification Microorganisms Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
Cholestenone (4-cholesten-3-one) is an orally available antimicrobial agent that is metabolized primarily in the liver as an intermediate oxidation product of cholesterol. Cholestenone inhibits human dermal fibroblast migration and fights Helicobacter pylori infection in vitro and in mouse models by inhibiting cholesterol-α-D-glucopyranoside (CGL). Cholestenone also alleviates metabolic disorders caused by obesity in db/db mice .

HY-W011641

(±)-Naringenin 3 Publications Verification	Cardiovascular Disease Structural Classification Flavonoids other families Classification of Application Fields Flavonones Source classification Phenols Polyphenols Plants Disease Research Fields	Potassium Channel Toll-like Receptor (TLR) NF-κB Apoptosis Caspase
(±)-Naringenin is an orally available anti-inflammatory agent that can regulate both acute and chronic inflammation responses, while also showing antioxidant, neuroprotective, liver-protective, and anti-cancer effects. (±)-Naringenin promotes vasodilation in endothelial cells by activating BK_Ca channels in muscle cells. It also exerts protective effects against experimental colitis by inhibiting Toll-like receptor 4/NF-κB signaling, making it useful in studies related to sepsis, fulminant hepatitis, fibrosis, and cancer research .

HY-W006405R

Isoflavone (Standard)	Structural Classification Flavonoids Leguminosae Glycine max (L.) merr Source classification Plants Isoflavones	Others
Isoflavone (Standard) is the analytical standard of Isoflavone. This product is intended for research and analytical applications. Isoflavone is an orally available bioactive component of soy phytoestrogen with lipid-lowering and antioxidant activities. Isoflavone prevents a variety of chronic diseases by regulating fatty acid oxidation in the liver and gene expression in adipose tissue. In addition, isoflavone has important value in the research of cancer and cardiovascular diseases .

HY-B2171AR

Carubicin (hydrochloride) (Standard)	Quinones Structural Classification Microorganisms Anthraquinones Source classification Phenols Polyphenols	Apoptosis
Isoflavone (Standard) is the analytical standard of Isoflavone. This product is intended for research and analytical applications. Isoflavone is an orally available bioactive component of soy phytoestrogen with lipid-lowering and antioxidant activities. Isoflavone prevents a variety of chronic diseases by regulating fatty acid oxidation in the liver and gene expression in adipose tissue. In addition, isoflavone has important value in the research of cancer and cardiovascular diseases .

HY-N6660

Trisdecanoin Tricaprin; Glyceryl tridecanoate	Ketones, Aldehydes, Acids Source classification umbellularia californica Metabolic Disease Plants Lauraceae Disease Research Fields	Endogenous Metabolite Androgen Receptor
Trisdecanoin (Tricaprin; Glyceryl tridecanoate) is an orally available precursor of decanoic acid (DA precursor) that can be hydrolyzed to decanoic acid. Trisdecanoin and its metabolite capric acid not only provide the body with a quick source of energy, but can also affect lipid metabolism. Trisdecanoin is a major component of medium chain triglycerides (MCT), which has preventive or inhibitory properties for abdominal aortic aneurysms (AAA), inhibition of cardiovascular disease, and anti-androgen (NSAA) and anti-hyperglycemic properties. Trisdecanoin can be used as an additive in food, medicine and cosmetics .

HY-B1350A

Fusidic acid sodium salt 2 Publications Verification Sodium fusidate; SQ-16360	Infection Triterpenes Structural Classification Microorganisms Classification of Application Fields Terpenoids Source classification Disease Research Fields Cancer	Bacterial Antibiotic Interleukin Related
Fusidic acid sodium salt is an orally available antibacterial agent that inhibits bacterial protein synthesis by preventing the release of translation elongation factor G (EF-G) from ribosomes. Fusidic acid sodium salt inhibits the inhibitory and activating effects of interleukins IL-1 and IL-6 on glucose-induced insulin production and exhibits antidiabetic effects in a rat model. Fusidic acid sodium salt improves the symptoms of colitis in rats and inhibits the growth of Toxoplasma gondii and Listeria monocytogenes EGD in vitro, but not in mice .

HY-113329

Guanidinoethyl sulfonate Taurocyamine	Structural Classification Natural Products Other disease Classification of Application Fields Disease markers Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Guanidinoethyl sulfonate is an orally available, blood-brain permeable competitive inhibitor of taurine transporters and a competitive antagonist of glycine receptors (GlyR) (IC₅₀=565 μM). Guanidinoethyl sulfonate has both weak agonist and antagonist effects on GABA_A receptors. Guanidinoethyl sulfonate inhibits taurine transmembrane transport and competitively binds to the GlyR ligand binding domain, thereby blocking glycine-mediated chloride influx, and may regulate brain pH to exert neuroprotective effects. Guanidinoethyl sulfonate can be used for neuroprotection studies of ischemic brain injury .

HY-N6660R

Trisdecanoin (Standard)	Ketones, Aldehydes, Acids Source classification umbellularia californica Plants Lauraceae	Endogenous Metabolite Androgen Receptor
Trisdecanoin (Standard) is the analytical standard of Trisdecanoin. This product is intended for research and analytical applications. Trisdecanoin (Tricaprin; Glyceryl tridecanoate) is an orally available precursor of decanoic acid (DA precursor) that can be hydrolyzed to decanoic acid. Trisdecanoin and its metabolite capric acid not only provide the body with a quick source of energy, but can also affect lipid metabolism. Trisdecanoin is a major component of medium chain triglycerides (MCT), which has preventive or inhibitory properties for abdominal aortic aneurysms (AAA), inhibition of cardiovascular disease, and anti-androgen (NSAA) and anti-hyperglycemic properties. Trisdecanoin can be used as an additive in food, medicine and cosmetics .

HY-N6985

Baccatin III 1 Publications Verification	Structural Classification Classification of Application Fields Terpenoids Taxaceae Source classification Diterpenoids Plants Disease Research Fields Taxus chinensis (Pilger) Rehd. Cancer	Others
Baccatin III is an orally available, selective inhibitor of the TGF-β1 signaling pathway and myeloid-derived suppressor cell (MDSC) activation. Baccatin III targets the AKT/STAT6 and Smad2/3 pathways, blocking TGF-β1-induced fibroblast differentiation and MDSC-mediated immunosuppression. Baccatin III exerts anti-inflammatory and anti-fibrotic effects by inhibiting macrophage activation and extracellular matrix deposition, and shows potential in the treatment of pulmonary fibrosis and cancer in terms of regulating the tumor immune microenvironment[1][2].

HY-N2038

3,5,6,7,8,3',4'-Heptemthoxyflavone	Structural Classification Flavonols Flavonoids Rutaceae Plants Citrus reticulata Blanco	Phosphodiesterase (PDE)
3,5,6,7,8,3',4'-Heptemthoxyflavone, a flavonoid from satsuma peel, is an orally available CREB activator with anti-tumor and anti-neuroinflammatory activity. 3,5,6,7,8,3',4'-Heptemthoxyflavone inhibits collagenase activity and increases the content of type I procollagen in human dermal fibroblast neoblast (HDFn) cells. 3,5,6,7,8,3',4'-Heptemthoxyflavone induces brain-derived neurotrophic factor (BDNF) expression through the cAMP/ERK/CREB signaling pathway and reduces phosphodiesterase activity in C6 glioma .

HY-111355B

Cholesteryl sulfate sodium	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
Cholesteryl sulfate sodium is an orally available, NPC2-targeted cholesterol biosynthesis agonist. Cholesteryl sulfate sodium activates SREBP2 by competitively binding to NPC2, promoting cholesterol synthesis (EC₅₀=50 μM). Cholesteryl sulfate sodium enhances the self-assembly ability of Mitoxantrone hydrochloride (HY-13502A), while repairing the intestinal mucosal barrier and inhibiting inflammation by regulating serine protease activity and PKCη signaling pathway. Cholesteryl sulfate sodium is a component of the platelet cell membrane and supports platelet adhesion. Cholesteryl sulfate sodium also regulates the activity of selective protein kinase C isoforms and modulates the specificity of PI3K, playing a role in keratinocyte differentiation .

HY-N2038R

3,5,6,7,8,3',4'-Heptemthoxyflavone (Standard)	Structural Classification Flavonols Flavonoids Rutaceae Plants Citrus reticulata Blanco	Phosphodiesterase (PDE)
3,5,6,7,8,3',4'-Heptemthoxyflavone (Standard) is the analytical standard of 3,5,6,7,8,3',4'-Heptemthoxyflavone (HY-N2038). This product is intended for research and analytical applications. 3,5,6,7,8,3',4'-Heptemthoxyflavone, a flavonoid from satsuma peel, is an orally available CREB activator with anti-tumor and anti-neuroinflammatory activity. 3,5,6,7,8,3',4'-Heptemthoxyflavone inhibits collagenase activity and increases the content of type I procollagen in human dermal fibroblast neoblast (HDFn) cells. 3,5,6,7,8,3',4'-Heptemthoxyflavone induces brain-derived neurotrophic factor (BDNF) expression through the cAMP/ERK/CREB signaling pathway and reduces phosphodiesterase activity in C6 glioma .

Cat. No.	Product Name	Chemical Structure

HY-12085S

Apremilast-d5
Apremilast-d₅ is a deuterium labeled Apremilast. Apremilast is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC50 of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC50 of 104 nM[1].

HY-10159S

Nilotinib-d6
Nilotinib-d₆ is a deuterium labeled Nilotinib. Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity[1].

HY-132549S

Nilotinib-d3
Nilotinib-d₃ is the deuterium labeled Nilotinib. Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity[1][2].

HY-16774S

Vericiguat-d3 hydrochloride
Vericiguat-d3 (BAY1021189-d3) hydrochloride is a deuterated Vericiguat with tracer functionality. Vericiguat is an orally available stimulator of guanylate cyclase .

HY-B0177S

Tinidazole-d5
Tinidazole-d₅ is the deuterium labeled Tinidazole. Tinidazole, an orally available antibacterial agent, is a 5-nitroimidazole with selective activity against anaerobic bacteria and protozoa[1].

HY-14806S

Teneligliptin-d8
Teneligliptin-d₈ is a deuterium labeled Teneligliptin (MP-513). Teneligliptin is a potent, orally available, competitive, and long-lasting DPP-4 inhibitor[1].

HY-14870S3

Selexipag-d6
Selexipag-d₆ is deuterium labeled Selexipag. Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI2) receptor (IP receptor).

HY-10159S1

Nilotinib-13C,d3
Nilotinib-13C,d3 is a deuterated labeled Nilotinib . Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.

HY-14272S

Ravuconazole-d4
Ravuconazole-d₄ is the deuterium labeled Ravuconazole. Ravuconazole (BMS-207147) is an orally available triazoleantifungle agent that potently inhibits a wide range of fungi[1][2].

HY-17359S

Deferasirox-d4
Deferasirox-d₄ is the deuterium labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload[1][2][3].

HY-14870S1

Selexipag-d7
Selexipag-d₇ is the deuterium labeled Selexipag. Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (PGI2) receptor (IP receptor)[1][2].

HY-40354S

Tofacitinib-13C3
Tofacitinib- ¹³C₃ is the ¹³C-labeled Tofacitinib. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively.

HY-W751099

Corticosterone-13C3
Corticosterone- ¹³C₃ is a ¹³C-labeled corticosterone (HY-B1618). Corticosterone (17-Deoxycortisol) is an orally available glucocorticoid that can regulate limbic system neurons and has good immunosuppressive activity.

HY-19822S1

Elacestrant-d4-1
Elacestrant-d₄-1 is the deuterium labeled Elacestrant (HY-19822). Elacestrant is an orally available and selective estrogen receptor degrader (SERD) with IC₅₀s of 48 and 870 nM for ERα and ERβ, respectively .

HY-32721S

Neratinib-d6
Neratinib-d₆ (HKI-272-d6) is the deuterium labeled Neratinib. Neratinib (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor with IC50s of 59 nM and 92 nM for HER2 and EGFR, respectively.

HY-40354AS

Tofacitinib-d3 citrate
Tofacitinib-d₃ (citrate) is deuterium labeled Tofacitinib (citrate). Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.

HY-40354S1

Tofacitinib-13C3,15N
Tofacitinib- ¹³C₃, ¹⁵N (Tasocitinib- ¹³C₃, ¹⁵N) is ¹³C and ¹⁵N labeled Tofacitinib. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

HY-13904S

Flumatinib-d3
Flumatinib-d₃ is deuterium labeled Flumatinib. Flumatinib (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively[1].

HY-12296S

Navtemadlin-d7
Navtemadlin-d₇ is the deuterium labeled Navtemadlin. Navtemadlin (AMG 232) is a potent, selective and orally available inhibitor of p53-MDM2 interaction, with an IC50 of 0.6 nM. Navtemadlin binds to MDM2 with a Kd of 0.045 nM[1][2].

HY-19822S2

Elacestrant-d10
Elacestrant-d₁₀ is the deuterium labeled of Elacestrant (HY-19822). Elacestrant is an orally available and selective estrogen receptor degrader (SERD) with IC₅₀s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant also inhibits growth of ER ⁺ breast cancer cell lines in vitro and in vivo .

HY-157585S

21-Dehydro Budesonide-d8-1
21-Dehydro Budesonide-d8-1 is deuterated labeled dehydrogenated Budesonide (HY-13580). Budesonide is an orally available glucocorticoid receptor agonist with anti-cancer activity. 21-Dehydro Budesonide-d8-1 acts as a probe for glucocorticoid receptors and is used in isotope tracing studies .

HY-12085S1

Apremilast-d8
Apremilast-d₈ (CC-10004-d₈) is deuterium labeled Apremilast. Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC₅₀ of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC₅₀ of 104 nM .

HY-14806S1

Teneligliptin-d4
Teneligliptin-d₄ is deuterium labeled Teneligliptin. Teneligliptin (MP-513) is a potent, orally available, competitive, and long-lasting DPP-4 inhibitor. Teneligliptin competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50s of approximately 1 nM[1].

HY-12085S3

Apremilast-d3
Apremilast-d₃ (CC-10004-d₃) is deuterium labeled Apremilast. Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC₅₀ of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC₅₀ of 104 nM .

HY-13011S1

Alectinib-d6
Alectinib-d₆ is deuterium labeled Alectinib. Alectinib (CH5424802) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively[1]. Alectinib demonstrates effective central nervous system (CNS) penetration[2].

HY-13011S

Alectinib-d8
Alectinib-d₈ is the deuterium labeled Alectinib. Alectinib (CH5424802) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively[1]. Alectinib demonstrates effective central nervous system (CNS) penetration[2].

HY-111372S

Finerenone-d3

Finerenone-d3 is the deuterium labeled finerenone (HY-111372). Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

HY-13010S

Laquinimod-d5

Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

HY-111372S1

Finerenone-d5

Finerenone-d₅ (BAY 94-8862-d₅) is deuterium labeled Finerenone. Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

HY-117287

Deucravacitinib

15+ Cited Publications

Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC₅₀=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis .

HY-12678S1

Entrectinib-d8

Entrectinib-d8 (NMS-E628-d8; RXDX-101-d8) is a deuterated version of Entrectinib (HY-12678). Entrectinib (NMS-E628) is an orally available, blood-brain barrier permeable, central nervous system active TrkA/B/C, ROS1 and ALK inhibitor with IC₅₀ values of 1, 3, 5, 12 and 12, respectively. 7 nM. Entrectinib induces apoptosis and cycle arrest in cancer cells, has anti-tumor activity, and also alleviates bleomycin-induced pulmonary fibrosis in mice .

Cat. No.	Product Name		Classification

HY-151829

Fmoc-L-Asn(EDA-N3)-OH		Azide
Fmoc-L-Asn(EDA-N3)-OH is a click chemistry reagent containing an azide group. This building block is reported in literature for the modification of Amanitin via Click Chemistry. Alpha-Amanitin is the deadliest member of the amatoxin peptide family produced by the death-cap mushroom A. phalloides. It is an orally available, rigid, bicyclic octapeptide and one of the most lethal known natural products (LD50 = 50-100 μg/kg) acting as highly selective allosteric inhibitor of the RNA polymerase II . It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Oral availability

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products